Hepion Pharmaceuticals, Inc.

DB:336 Stock Report

Market Cap: €26.5m

Hepion Pharmaceuticals Management

Management criteria checks 2/4

Hepion Pharmaceuticals' CEO is Bob Foster, appointed in Jun 2016, has a tenure of 7.17 years. total yearly compensation is $725.83K, comprised of 73.5% salary and 26.5% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth €16.40K. The average tenure of the management team and the board of directors is 3.8 years and 3.6 years respectively.

Key information

Bob Foster

Chief executive officer

US$725.8k

Total compensation

CEO salary percentage73.5%
CEO tenure7.2yrs
CEO ownership0.06%
Management average tenure3.8yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Foster's remuneration changed compared to Hepion Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$726kUS$533k

-US$45m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$700kUS$500k

-US$33m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$22m

Dec 31 2020US$2mUS$400k

-US$20m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$621kUS$400k

-US$12m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$20m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$375kUS$312k

-US$18m

Compensation vs Market: Bob's total compensation ($USD725.83K) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.

CEO

Bob Foster (65 yo)

7.2yrs

Tenure

US$725,833

Compensation

Dr. Robert T. Foster, also known as Bob, B.Sc (Pharm), Pharm D., Ph D., has been Chief Executive Officer at Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.) since October 3, 2018, Di...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Foster
President7.2yrsUS$725.83k0.062%
€ 16.4k
John Cavan
Chief Financial Officer7.4yrsUS$495.33k0.020%
€ 5.2k
Todd Hobbs
Chief Medical Officer2.5yrsUS$578.00kno data
Launa Aspeslet
Chief Operating Officer1.2yrsno datano data
Sharen Pyatetskaya
Director of Investor Relationsno datano datano data
Daniel Trepanier
Senior Vice President of Drug Development3.8yrsno datano data
Patrick Mayo
Senior Vice President of Clinical Pharmacology3.8yrsno datano data
John Sullivan-Bolyai
Part-Time Consultant5.7yrsUS$34.62kno data
Stephen Harrison
Scientific Advisory Board Chair & Consultant Medical Director3.8yrsno datano data

3.8yrs

Average Tenure

65yo

Average Age

Experienced Management: 336's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Foster
President4.8yrsUS$725.83k0.062%
€ 16.4k
Stephen Harrison
Scientific Advisory Board Chair & Consultant Medical Director4yrsno datano data
John Brancaccio
Independent Director10.3yrsUS$86.00k0.0092%
€ 2.4k
Gary Jacob
Independent Chairman of the Board10.3yrsUS$102.50k0.016%
€ 4.2k
Timothy M. Block
Independent Director9.8yrsUS$77.90kno data
Petrus L. Wijngaard
Independent Director3.2yrsUS$79.50k0.039%
€ 10.4k
Rohit Loomba
Member of Scientific Advisory Boardless than a yearno datano data
Nikolai Naoumov
Member of Scientific Advisory Boardless than a yearno datano data
Philippe Gallay
Member of Scientific Advisory Board7.1yrsno datano data
Anand Reddi
Independent Director1.2yrsUS$30.92kno data
Yury Popov
Member of Scientific Advisory Boardless than a yearno datano data
Kaouthar Lbiati
Independent Director1.2yrsUS$30.92kno data

3.6yrs

Average Tenure

65yo

Average Age

Experienced Board: 336's board of directors are considered experienced (3.6 years average tenure).